Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) ((DeLLphi-310))
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1J 1Z4
- CHU de Quebec Hopital de l Enfant Jesus
-
-
-
-
-
Fuzhou, China, 350011
- Fujian Cancer Hospital
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Shandong Cancer Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 611135
- West China Hospital of Sichuan University
-
-
-
-
-
Bordeaux, France, 33000
- Institut Bergonie
-
Lyon, France, 69373
- Centre Léon Bérard
-
Toulouse, France, 31059
- Institut Universitaire du Cancer Toulouse Oncopole
-
Villejuif, France, 94805
- Gustave Roussy
-
-
-
-
-
Essen, Germany, 45147
- Universitaetsklinikum Essen
-
-
-
-
-
Athens, Greece, 11528
- Alexandra Hospital
-
Athens, Greece, 11526
- Henry Dunant Hospital Center
-
Thessaloniki, Greece, 57001
- European Interbalkan Medical Center
-
Thessaloniki, Greece, 57001
- Iatriko Diavalkaniko Thessalonikis
-
-
-
-
-
Budapest, Hungary, 1083
- Semmelweis Egyetem
-
Gyöngyös, Hungary, 3200
- Clinexpert Kft Bugat Pal Korhaz
-
-
-
-
-
Candiolo to, Italy, 10060
- Istituto di Candiolo Fondazione del Piemonte per l Oncologia IRCCS
-
Meldola (FC), Italy, 47014
- Istituto Romagnolo Per Lo Studio dei tumori Dino Amadori
-
Milan, Italy, 20162
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
-
-
-
-
Seoul, South Korea, 03080
- Seoul National University Hospital
-
Seoul, South Korea, 05505
- Asan Medical Center
-
Seoul, South Korea, 03722
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
-
Catalonia
-
Barcelona, Catalonia, Spain, 08041
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Catalonia, Spain, 08035
- Hospital Universitari Vall D Hebron
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
-
-
California
-
Irvine, California, United States, 92618
- City of Hope Orange County Lennar Foundation Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Siteman Cancer Center
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- Sanford Roger Maris Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 54104
- Sanford Oncology Clinic and Pharmacy
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Medical Center
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants ≥ 18 years of age (or legal adult age within country) at time of signing informed consent.
- Participants with histologically or cytologically confirmed ES-SCLC.
- For Parts 1 and 2, subjects must have ES-SCLC that has progressed or recurred following at least 1 prior line of platinum-based anti-cancer therapy received either for LS-SCLC or ES-SCLC.
- For Part 3, subjects must have ES-SCLC and no prior systemic treatment for ES SCLC other than 1 cycle of platinum-based chemotherapy, and etoposide, and with or without PD-(L)1 inhibitor in the first-line setting.
- At least 1 measurable lesion as defined by RECIST 1.1.
- Participants must have adequate organ function (cardiac, pulmonary, kidney, bone marrow, and liver).
Exclusion Criteria:
- Prior delta-like ligand 3 (DLL3) or B7 homolog 3 (B7-H3) targeted therapy.
- Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.
- Symptomatic central nervous system (CNS) metastases. Note: Participants with asymptomatic brain metastases are eligible as defined in the protocol.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Baseline requirement of supplemental oxygen.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Exploration (Part 1)
Multiple dose levels of YL201 will be explored in combination with tarlatamab administered intravenously (IV) at a fixed dose using one-step dosing.
|
Tarlatamab will be administered as an IV infusion.
YL201 will be administered as an IV infusion.
|
|
Experimental: Dose Expansion (Part 2)
YL201 will be administered at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV at a fixed dose.
|
Tarlatamab will be administered as an IV infusion.
YL201 will be administered as an IV infusion.
|
|
Experimental: Triplet Combination (Part 3)
YL201 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) administered IV at a fixed dose.
|
Tarlatamab will be administered as an IV infusion.
YL201 will be administered as an IV infusion.
Durvalumab will be administered as an IV infusion.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants Experiencing Dose-limiting toxicities (DLTs)
Time Frame: Up to Day 21
|
Up to Day 21
|
|
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Duration of Response (DOR) per RECIST 1.1
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Time to Response (TTR) per RECIST 1.1
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Disease Control Rate (DCR) per RECIST 1.1
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Progression-free Survival (PFS) per RECIST 1.1
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Time to Progression (TTP) per RECIST 1.1
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Time to Subsequent Therapy
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Overall Survival (OS)
Time Frame: Up to 3.5 Years
|
Up to 3.5 Years
|
|
Maximum Serum Concentration (Cmax) of Tarlatamab
Time Frame: Up to Week 36
|
Up to Week 36
|
|
Minimum Serum Concentration (Cmin) of Tarlatamab
Time Frame: Up to Week 36
|
Up to Week 36
|
|
Area Under the Concentration-time Curve (AUC) Over the Dosing Interval for Tarlatamab
Time Frame: Up to Week 36
|
Up to Week 36
|
|
Half-life (t1/2) of Tarlatamab
Time Frame: Up to Week 36
|
Up to Week 36
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Small Cell Lung Carcinoma
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- durvalumab
Other Study ID Numbers
Other Study ID Numbers
- 20240124 (JohannesGU)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.